Opus Genetics financials
$4.96−1.88%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $14.2M | $11.0M |
| Gross profit | $14.2M | $11.0M |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$38.6M | -$62.1M |
| Net income | -$49.6M | -$57.5M |
| Net margin | −349.3% | −523.4% |
| Diluted EPS | $-0.80 | $-2.15 |
| EBITDA | -$38.5M | -$62.1M |
| Operating cash flow | -$35.3M | -$25.6M |
| Free cash flow | -$35.3M | -$25.6M |
| Diluted shares | 62.2M | 26.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $45.1M | $30.3M |
| Short-term investments | $0.00 | $2.0K |
| Total debt | $0.00 | $0.00 |
| Total assets | $50.2M | $36.9M |
| Total liabilities | $34.9M | $11.3M |
| Shareholders' equity | $15.3M | $6.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology